Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Anaplastic Oligodendroglioma

Oliver JonasSmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Anaplastic Oligodendroglioma cohort.

Asset / SponsorPhaseRating
gsk1120212
Novartis Pharmaceuticals
Phase 4BB
Carboplatin
Oliver Jonas
Phase 2BB
CARMUSTINE
Shandong Lanjin Pharmaceuticals Co.,Ltd
Phase 3BB
Dabrafenib
Novartis Pharmaceuticals
Phase 4BB
MERCAPTOPURINE ANHYDROUS
Emory University
Phase 2B

View all 50 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →